2026.02.10

決算説明会資料（2025年12月期）(Japanese only)

2025.08.18

Analyst Report[Full report] (Shared Research)

2025.08.12

2025年12月期中間決算説明会の動画を掲載しました。(Japanese only)

2025.08.12

SymBio Announces Abstract on Brincidofovir for the Treatment of Malignant Brain Tumors (Glioblastoma) Accepted for Presentation at the Society for Neuro-Oncology (SNO) Annual Meeting to be Held in November 2025

2025.08.05

中間決算説明会資料（2025年12月期）(Japanese only)

2025.07.28

SymBio to Present Preclinical Data on Brincidofovir in Head and Neck Cancer at ESMO 2025 Congress

2025.06.30

SymBio Submits Clinical Trial Application for a Phase 3 Global Study Evaluating IV Brincidofovir for the Treatment of Adenovirus Infection after HSCT

2024.07.12

SymBio Pharmaceuticals Announces Publication of Research Showing Antiviral Drug Brincidofovir Inhibits Infectious Viral Production of Polyomavirus

2023.11.17

Notice of Relocation of Head Office

2023.11.06

SymBio To Present Positive Data from Ongoing Phase 2a Study of IV Brincidofovir in Adenovirus Infection in Oral Presentation at the 65th American Society of Hematology (ASH) Annual Meeting

2023.10.12

The Results of CRADA Study on Brincidofovir in Multiple Sclerosis Presented at the 9th Joint ECTRIMS-ACTRIMS Meeting

2023.07.20

Notice of Personnel Changes at SymBio Pharma USA, Inc.

2023.06.12

Presentation of the Results of Biomarker Research Predicting the Antitumor Effects of Brincidofovir at the 17th ICML

2023.05.29

IV Brincidofovir in Adenovirus Infection achieved POC in Phase 2 Clinical Trial

2023.04.24

SymBio enters into a CRADA to Assess Efficacy of Brincidofovir for Epstein-Barr Virus Associated Lymphoproliferative Disease

2023.03.22

Development of Brincidofovir for Multiple Sclerosis CRADA with the National Institute of Neurological Disorders and Stroke (NINDS)